You are here: Home » 2023 » May » Archives for 12th

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Telephone and Data Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDS, TDSPrU, TDSPrV

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telephone and Data Systems, Inc. (the "Company" or "TDS") (NYSE: TDS, TDSPrU, TDSPrV) between May 6, 2022 and November 3, 2022, both dates inclusive (the "Class Period"), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased TDS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TDS class action, go to https://rosenlegal.com/submit–form/?case_id=15807 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Company and its subsidiary, United States Cellular Corporation (“UScellular”), made false and/or misleading statements and/or failed to disclose that: (1) defendants had no reason to believe UScellular's "free upgrade" promotional activity, which was tested and trialed during the second quarter of 2022, was effective at reducing the Company's postpaid churn rate as they represented to investors, as opposed to merely adding new postpaid subscribers, when its churn rate was actually increasing or remaining constant over most quarters in the class period; (2) UScellular was not making progress with respect to its churn rate, as it represented to investors; (3) UScellular was not in fact balancing its promotional activity and its profitability; (4) due to extreme competition among postpaid carriers, UScellular did not have the flexibility to offset the costs from widespread, expensive promotions with price increases; and (5) as a result of the Companies' decision for UScellular to continue engaging in heavy promotions to address its postpaid subscriber churn rate despite any lack of positive impact on churn rate, UScellular's profitability substantially declined. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TDS class action, go to https://rosenlegal.com/submit–form/?case_id=15807 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8838498)

Tri Ri Asset Management announces launch of Flagship VC fund

NERW YORK, May 12, 2023 (GLOBE NEWSWIRE) — Tri Ri Asset Management (“TRAM”) today announced the launch of their flagship venture capital fund, the TRAM Venture Fund (“TRAM VF”), with a target size of USD 125 million. TRAM VF will be focused on the MENA region, with a particular emphasis in Pakistan. Tri Ri Asset Impact Fund, with a commitment of USD 50 million, serves as the fund's anchor. TRAM VF is dedicated to serving the later–stage tech company growth needs in Pakistan and MENA. The new fund's deployment will focus on investing in innovative early–stage and growth–stage tech companies and enabling them to emerge into market leaders in GCC, South Asia, and North Africa.

TRAM VF will meet the needs of local startups and help them to become regional and global competitors. The local tech industry has recently seen substantial expansion; yet, funding is falling behind the quick speed of change and technological adoption. This has drawn global technology businesses as well as international venture capitalists to the region. TRAM VF will further accelerate the growth of the VC ecosystem in order to meet the increasing demand for technology products and services.

Adeel Hussain, General Partner of TRAM VF stated: “Following the successful launch of our PE Impact fund last year, we are pleased to announce the launch of our Flagship VC Fund TRAM VF and its initial closure of $92 million. A particular thanks to our anchor investor, as well as the LP a Swiss family office, whose commitment demonstrates how ripe the region is for VC investments.”

Asad Ali, Co–CIO & Principal added: "We look forward to deploying our first flagship VC fund in a region with such complex growth. Scaling from our roots in Real Estate our capital deployment strategy has always been the core of our rapid growth. We will be able to use the same strategies to assist early stage startups within the region to leverage and grow their business. Our investment strategy is defined by a data–driven approach, specialized sourcing capabilities, and an uncompromising commitment to meaningful collaboration with entrepreneurs. We are more than just investors; we are also builders, utilising our team's market experience to propel firms more precisely than generalist organisations. Supporting entrepreneurs is a privilege that we never take for granted."

TRAM VF will utilize its differentiated market expertise and metrics–driven evaluation process, to invests across Fintech, healthcare, consumer, education, food security, real estate, fintech, B2B, Artificial Intelligence across the region.

About Tri Ri Asset Management:
Tri Ri Asset Management, is a concentrated, research–intensive, fundamental value investor in the public markets. Since 2019, Tri Ri has executed an aggressive but disciplined growth strategy, building a balanced portfolio of public market and real estate holdings.
As of March 2023, Tri Ri's portfolio composed of USD 850 million in assets under management along with USD 1.2 billion in Co–investments and 7 renowned properties with over 1500 rooms.


GLOBENEWSWIRE (Distribution ID 8838768)

Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)–driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15–19. He will deliver a keynote presentation on "The State of the Science in Disease Modeling Across Diverse Indications" on May 15 at 11AM at the Hynes Convention Center and join in an interactive discussion on May 15 at 12:45PM.

In his presentation, Dr. Zhavoronkov will make the first announcement of peptide–based drug design strategies and Generative Biologics, a new engine that belongs to the company's end–to–end AI–driven drug discovery platform Pharma.AI that leverages hundreds of millions of biological data points, machine learning algorithms, and generative biology models to build and design polypeptides from scratch.

A team of expert scientists are developing Pharma.AI at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region's largest AI–powered biotechnology research center.

"We are at an exciting moment in the history of generative AI in drug discovery," says Zhavoronkov. "Thanks to years of accumulated data and technological advances in generative AI, we can find targets and design new small molecules for hard–to–treat diseases with incredible speed and efficiency working in close partnership with pharmaceutical companies. We look forward to using generative AI to explore diverse drug development strategies."

Insilico Medicine was one of the first companies to use generative adversarial autoencoders for de–novo drug discovery. In 2016, the Company introduced the earliest iternation of its generative biology tool for identifying novel targets with a publication in Nature Communications. Another publication followed in Oncotarget, demonstrating how Insilico could employ generative algorithms with reinforcement learning to design novel small molecules with predefined and optimized properties. By 2018, Insilico integrated generative biology and chemistry approaches into the commercially available Pharma.AI platform that accelerates the process of lead discovery from years to days, and is currently being utilized by 11 of 20 top pharmaceutical companies.

The Company has also utilized the platform to develop its own robust pipeline of assets, including two drugs "" for idiopathic pulmonary fibrosis and COVID–19 "" currently in clinical trials and many potentially best–in–class and first–in–class assets in preclinical stages of development available for licensing. In total, Insilico has 31 programs across 29 targets, including in fibrosis, oncology, immunology, and central nervous system disorders.

Zhavoronkov says PEGS, the world's largest gathering of protein engineering and biotherapeutics experts, is the perfect setting for announcing the latest developments to Insilico's platform. "We were instrumental in the early development of generative biology and generative chemistry, and now we're advancing AI–designed drugs into clinical trials. It is truly a pivotal moment."

About Insilico Medicine

Insilico Medicine, a clinical–stage generative artificial intelligence (AI)–driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next–generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging–related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region's largest AI–powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico's end–to–end AI–driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.

For more information, visit www.insilico.com

Attachment


GLOBENEWSWIRE (Distribution ID 8838633)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vertex Energy, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – VTNR

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vertex Energy, Inc. (NASDAQ: VTNR) between April 1, 2022 and August 8, 2022, both dates inclusive (the "Class Period"), of the important June 12, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Vertex Energy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Vertex Energy class action, go to https://rosenlegal.com/submit–form/?case_id=12724 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) prior to the acquisition of the Mobile refinery, defendants had entered into inventory and crack spread hedging derivatives that significantly capped the profit margins on 50% of the Mobile refinery's expected output over the period April 1, 2022 to September 30, 2022, affecting over 6.5 million barrels of refined fuel output; (2) as a result, the hedges severely limited Vertex's ability to capitalize on the record–high crack spreads that existed at the time of the acquisition and resulted in over $90 million in losses in the second quarter of fiscal year 2022; (3) prior to the acquisition of the Mobile refinery, defendants had entered into an inventory intermediation agreement with the investment bank Macquarie Group, whereby Macquarie purchased (from third parties), owned, and sold (to Vertex) all crude oil inventory to be used at the Mobile refinery and also purchased (from Vertex), owned, and sold (to third parties) all refined fuel inventory produced at the Mobile refinery; (4) as a result, the strict terms of the arrangement, including requiring Vertex to purchase hedges to protect Macquarie's position in holding the crude and refined inventory, combined with the fact that the oil market was in a state of backwardation in early 2022, resulted in Vertex incurring significant fees and inventory losses; (5) prior to the acquisition of the Mobile refinery, defendants had entered into an inventory purchase agreement with Shell Oil as part of the Mobile acquisition agreement, which Vertex was forced to pay Shell Oil above–market prices for the additional crude oil inventory because of the state of backwardation in the oil market; (6) immediately following the acquisition of the Mobile refinery, Vertex experienced production issues that caused significant shortfalls in refined fuel volumes; (7) following the acquisition of the Mobile refinery, defendants overstated the purported profit margins that could be achieved at the refinery; and (8) as a result of the above misrepresentations and concealed facts, the Mobile refinery did not "generate[] strong EBITDA" "[d]uring the first 30 days of operations," and the Mobile refinery transition was not "seamless." When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Vertex Energy class action, go to https://rosenlegal.com/submit–form/?case_id=12724 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8838501)

ROSEN, A LEADING LAW FIRM, Encourages Tupperware Brands Corporation Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action First Filed by the Firm – TUP

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tupperware Brands Corporation (NYSE: TUP) between March 10, 2021 and March 16, 2023, both dates inclusive (the "Class Period"), of the important May 19, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Tupperware securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Tupperware class action, go to https://rosenlegal.com/submit–form/?case_id=12606 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) Tupperware did not disclose its serious issues with internal controls; (2) Tupperware's financial statements, from its 2020 Annual Report to the present, included misstatements, particularly as it related to the Company's accounting for income taxes; (3) as a result, Tupperware would need to restate its previously filed financial statements for certain periods; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Tupperware class action, go to https://rosenlegal.com/submit–form/?case_id=12606 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8838499)

TSE INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Trinseo PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – TSE

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities Trinseo PLC (NYSE: TSE) between May 3, 2021 and March 27, 2023, both dates inclusive (the "Class Period"), of the important June 20, 2023 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Trinseo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Trinseo class action, go to https://rosenlegal.com/submit–form/?case_id=13711 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company's Bristol, Pennsylvania plant had a troubled safety record while under prior ownership and continued to be unsafe after the Company acquired it; (2) defendants did not sufficiently disclose specific risks related to conducting operations at that plant; (3) operating a chemical plant with an unsafe history and presently unsafe operations exposed the Company to a heightened risk of a chemical spill or other adverse event; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Trinseo class action, go to https://rosenlegal.com/submit–form/?case_id=13711 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8838497)

EQUITY ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Icahn Enterprises L.P. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IEP

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Icahn Enterprises L.P. (NASDAQ: IEP) between August 2, 2018 and May 9, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 10, 2023.

SO WHAT: If you purchased Icahn Enterprises securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Icahn Enterprises class action, go to https://rosenlegal.com/submit–form/?case_id=16028 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 10, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) Icahn Enterprises was inflating its net asset value; (2) the Company was using money taken in from new investors to pay out dividends to old investors; (3) as a result, the Company would become the subject of criminal and/or regulatory scrutiny; and (4) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Icahn Enterprises class action, go to https://rosenlegal.com/submit–form/?case_id=16028 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8838408)

UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)–driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification, available for free. Through seven lectures, the course guides participants through the latest insights in disease modeling and target discovery "" critical areas in biomedical research that involve using computational and experimental approaches to gain insights into the causes of diseases and identify potential targets for drug development.

The course uses case studies to illustrate the practical application of the concepts covered. In particular, learners will have the opportunity to explore a demo version of PandaOmics, Insilico Medicine's generative AI tool for target discovery, which is being developed by a team of scientists at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region's largest AI–powered biotechnology research center.

PandaOmics is used by numerous pharmaceutical companies and to develop the 31 pharmaceutical assets advancing in Insilico's own pipeline "" including two drugs for idiopathic pulmonary fibrosis and COVID–19 currently in clinical trials.

After completing the course, participants will gain: .

  • in–depth knowledge of the challenges and opportunities in drug target discovery, including the emerging role of AI, achievements, and failures of pharma companies in recent years and the most promising therapeutic areas;
  • practical skills in identifying and evaluating potential drug targets, including familiarity with several popular tools and resources;
  • knowledge of the latest trends and emerging topics in target discovery, such as the use of large language models and the evolution of the druggable genome concept;
  • exposure to several case studies that illustrate the practical application of the concepts covered, and the ability to critically evaluate and compare different target discovery strategies.

The course is geared toward anyone interested in drug discovery, biomedical research, and healthcare innovation, including researchers, scientists, pharmaceutical professionals and students pursuing a degree in molecular biology, chemistry, or related fields who want to see how fundamental science can be applied to the development of novel therapeutics.

"This course aligns with our larger mission to accelerate the discovery and development of new therapeutics by making technological breakthroughs accessible to all scientists, including students, who might be interested in pursuing AI drug discovery," says Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, who is one of the course instructors.

Insilico has supported young researchers in using its platform before. Three high school researchers used PandaOmics to uncover new targets for glioblastoma and aging, the results of which were recently published in the journal Aging. And Insilico has been a supporter of the Youth Longevity Association and annually sponsors young scientists to attend the Aging Research and Drug Discovery conference in Copenhagen, a signature event that Zhavoronkov cofounded.

About Insilico Medicine

Insilico Medicine, a clinical–stage generative artificial intelligence (AI)–driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next–generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging–related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region's largest AI–powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico's end–to–end AI–driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.

For more information, visit www.insilico.com

Attachments


GLOBENEWSWIRE (Distribution ID 8838367)

A Short Tale of a Tree and a Moroccan Wedding Party

The argan tree forest constitutes a vital fodder reserve for all herds even in periods of drought. All parts of the argan tree are edible and very appreciated: leaves, fruits and the undergrowth are a meal of choice especially for the most daring goats that do not hesitate to climb the branches. Credit: Shutterstock.

The argan tree forest constitutes a vital fodder reserve for all herds even in periods of drought. All parts of the argan tree are edible and very appreciated: leaves, fruits and the undergrowth are a meal of choice especially for the most daring goats that do not hesitate to climb the branches. Credit: Shutterstock.

By Baher Kamal
ROME, May 12 2023 – A much needed break amidst so many alarming news, with a brief story of a tree, a bottle of liquid gold, and a wedding gift.

It is useless to remind you that all trees are wonderful living beings, with an amazing vital system to drain water through their roots, and breathe through their leaves to bring this water to their trunk, branches and leaves.

All of them are sources of most of the oxygen on Earth while absorbing harmful greenhouse gases. Their roots greatly contribute to fixing the land, thus reducing the risk of further degradation and desertification. Let alone purifying the air.

 

This particular tree

Among them, one is special: the Argan tree.

A native species of the sub-Saharan, Southwest region of Morocco, where it grows in arid and semi-arid areas, this tree is the defining species of a woodland ecosystem, also known as Arganeraie, which is rich in endemic flora.

The argan tree used to grow throughout North Africa, but currently, it only grows in southwestern Morocco. It is estimated to be the second most abundant tree in Moroccan forests, with over 20 million trees living in the region.

The argan tree is one of the world’s wild plants, which are used by an estimated 3.5 to 5.8 billion people, with one billion humans depending on them for their livelihoods and food security.

Furthermore, wild plants offer great economic and nutritional benefits for these communities and for societies around the world. In fact, between 2000 and 2020, the global trade value of medicinal and aromatic plants alone increased by more than 75%, as reported by the UN Food and Agriculture Organization (FAO).

In spite of that, two in five of the world’s plant species are at risk of extinction due to habitat loss, sustainable use and climate change.

 

Hidden in plain sight

Here is the case of just one of these wild plant species hidden in plain sight:

Argan can be found in cosmetics, food and pharmaceuticals. Mostly used as an oil, its anti-ageing properties are popular for cosmetics, and its demand in the food industry has turned it into the most expensive edible oil in the world, FAO adds.

 

Under the burning sun

Now see what the UN further tells about its importance on the occasion of this year’s International Day of Argania:

  • It withstands temperatures of up to 50° Celsius.
  • It is a bastion against desertification, it can reach 10 metres in height and can live for 200 years.
  • Its woodlands provide forest products, fruits and fodder.
  • Its leaves and fruits are edible and highly appreciated, as is the undergrowth, and constitute a vital fodder reserve for all herds, even in periods of drought.
  • It is used as fuelwood for cooking and heating.
  • And also as medicines and cosmetics.

 

A mainstay of indigenous Berbers

For centuries, the argan tree has been a mainstay of the Berber and Arab-origin indigenous rural communities, which developed a specific culture and identity, sharing their traditional knowledge and skills through non-formal education, particularly the knowledge associated with the traditional production of argan oil by women, the world body explains.

The argan-based agro-forestry-pastoral system uses only locally adapted species and pastoralism activities and relies on traditional water management provided by the Matifiya – a rainwater reservoir carved into the rock, hence contributing to climate change mitigation and adaptation, and to the conservation of biodiversity.

 

The ‘liquid gold’

But there is more: the world-renowned argan oil, which is extracted from the seeds and has multiple applications, especially in traditional and complementary medicine and in the culinary and cosmetic industries.

In addition, argan oil is given as a wedding gift and it is used extensively in the preparation of festive dishes.

The fruit of the argan tree is a green to light yellow berry in the centre of which is an almond made up of several seeds gorged with oil. It takes about 150 kg of fruit to produce 3 litres of argan oil.

 

The Argan Women

Indeed, it is said that, since the 13th century, the Berber women of North Africa have been making argan oil for culinary and cosmetic purposes.

The International Day of Argania further explains that the fruits are hand-picked and dried in the sun, then pulped, grinding, sorting, milling and mixing. Its nuts are crushed and its almonds crushed to filter the oil.

Women lead the entire extraction process through knowledge transmitted from one generation to the next. In fact, rural women and, to a lesser extent, men living in the reserve practice traditional methods to extract argan oil from the fruit of the tree.

“Traditional know-how specific to the extraction of the oil and its multiple uses is systematically transmitted by ‘argan women’, who teach their daughters from a young age to put it into practice.”

What else would you expect from a tree?

 

Violence Knows No Borders

A UNHCR emergency transit centre in Renk, South Sudan is receiving displaced people from Sudan. According to the UN, Sudan has a population of 48 million and is the third largest on the African continent. There are 25 UN entities operating in Sudan. Credit: UNHCR/Charlotte Hallqvist

By Richard Probst and Anna Reuss
CAIRO, Egypt / JUBA, South Sudan, May 12 2023 – Events in Sudan have been a constant topic of conversation in Cairo’s coffee houses since the violence erupted there four weeks ago. The images of almost 30 Egyptian soldiers briefly detained in Sudan by Rapid Support Forces (RSF) militias and the death of an Egyptian diplomat in Khartoum caused a stir in Egypt.

The detained soldiers were at the Merowe air base in northern Khartoum, run by Sudanese armed forces – officially for no more than an agreed training mission. However, the RSF and international observers assessed their presence as long-term support for the Sudanese army led by General Burhan.

For many Egyptians, these humiliating images produced a rally ‘round the flag effect. In a tragic way, they pointed to not only the geographical proximity but also the bond between the two neighbours.

In addition to the over 1,200-kilometre-long border in southern Egypt, the two countries have a multi-layered relationship visible not only in a common colonial past but also in the political developments of the past decade.

The outbreak of conflict between the RSF militias and the Sudanese army put an abrupt end to political developments led by the Sudanese military – a scenario with which the Egyptian leadership was comfortable.

In any case, Egypt has no interest in a destabilisation of Sudan and is calling on all sides for a permanent ceasefire. Political uncertainties on the country’s southern border and Sudan sinking into civil war are a worst-case scenario for Egypt. Sudan, which borders the Nile, is not only an important ally for Egypt on the issue of the Grand Ethiopian Renaissance Dam (GERD) project.

The Egyptian leadership is betting on the Sudanese military, seen by them as the best guarantor of their own interests.

The geopolitical jigsaw puzzle of different supporters for the two sides in the Sudanese conflict has placed Cairo in a diplomatic quandary. The United Arab Emirates (UAE), an important Egyptian ally, also supports the RSF, as does Libyan General Haftar, a close ally of Cairo in the conflict in Libya.

Egypt, which is right now in a severe economic and financial crisis, is dependent on investment from the Gulf region and in particular from the UAE. The conflict in Sudan has therefore a domestic political dimension as well. All this makes the conflict difficult for Egypt’s diplomacy to navigate.

Egypt can play an important and constructive role in the short term, in particular in persuading General Haftar not to deliver weapons from Libya to the crisis region. In the long term, it will be crucial for the region’s stability for civil actors to be involved in resolving the conflict in Sudan.

This should also be in Egypt’s long-term interest as it could avoid the scenario of an ongoing civil war. The situation on the Sudanese-Egyptian border is very tense at the moment. Thousands of refugees are making the long and costly journey from Khartoum to Cairo.

The few border crossings between Egypt and Sudan are the bottlenecks through which thousands of Sudanese refugees squeeze their way. The unresolved border conflict between the two countries in the Halaib Triangle further reduces the number of possible crossing points.

The United Nations High Commissioner for Refugees (UNHCR) estimated some 50,000 people to have crossed the border into Egypt in recent weeks. Even before the conflict broke out, around five million Sudanese were living in Egypt, most of them already for tens of years. Of these, just some 60,000 are registered with the UNHCR as refugees.

The Sudanese community – especially in Cairo – is therefore an important contact point and is playing a central role in taking in the refugees. In the long term, however, this will not be feasible. The longer the conflict lasts, the more important it will be to stand by Egypt and the UN organisations working in Egypt to support the refugees.

With all attention focused on the successful evacuation of international personnel from Sudan, the protection and support of the Sudanese refugees in Egypt and the other neighbouring countries must not be forgotten.

South Sudan

More than 30,000 people have fled Khartoum and the western Darfur region across the South Sudanese border since fighting broke out. The vast majority of them are South Sudanese, who, in the past, sought refuge in the north from violence and conflict south of the border.

The small border town of Renk, where most of those fleeing Khartoum arrive, is overwhelmed by the sheer amount of people. Humanitarian organisations are trying to get those arriving at the small airport in Paloch to continue their journey to Juba as quickly as possible.

But there are not enough flights, so, to prevent a humanitarian crisis in the border area, the government is now considering using barges on the Nile to take the refugees to other parts of South Sudan.

The arrival of tens of thousands of refugees is the most visible impact of the war between the two Sudanese generals on the country’s southern neighbour. The two Sudans remain deeply interlinked even after South Sudan gained independence in 2011.

But what worries the government in Juba most is the risk that Sudan’s oil export infrastructure will be deliberately destroyed in the course of the fighting. More than 90 per cent of South Sudan’s government revenue is generated from oil production. The ‘black gold’ reaches the international markets via Sudan. There is no alternative pipeline.

Currently, the Sudanese National Army is reportedly controlling the revenues from the pipeline user fees, no doubt to the chagrin of the RSF militia. An attack on the pipeline would have devastating economic consequences for Juba.

The responsible ministry is already complaining that the market price for South Sudanese oil has fallen owing to the situation in Sudan, with buyers taking advantage of the instability to drive down prices.

The joint interest of the South Sudanese government and the Sudanese army under General Burhan in maintaining oil exports is in turn likely to impact South Sudanese President Salva Kiir’s peace efforts. He has invited both parties to the conflict to mediation talks in Juba, so far without success.

South Sudanese activist Edmund Yakani warns that the crisis in Sudan is also endangering the peace process in South Sudan. Sudan is one of the two regional guarantors of the peace agreement that formally ended the civil war in 2018 and the actor with the most powerful leverage over the peace parties in Juba.

There is now a danger that the parties will continue to delay the peace process – also with the attention of the international community and other regional players now focused on Sudan. In addition, the instability in Sudan threatens to flush even more small arms across the border, while the brisk trade in everyday goods between North and South is suffering, further worsening the precarious supply situation.

All parties to the South Sudanese peace treaty, as well as armed groups fighting the transitional government, have links with various civilian and armed players in Sudan. How the conflict ends and who ultimately gains the upper hand will directly impact power dynamics in the political mêlée in Juba and the conflict landscape in the wider country.

Should the conflict continue and widen, both sides could also recruit keen-to-fight forces from South Sudan’s fragmented conflict landscape, who could later return with more weapons, combat experience and new external political backing.

Richard Probst is the Friedrich-Ebert-Stiftung’s office director in Egypt. Previously, he was the FES’ Regional Coordinator for Climate and Energy Policy in the Middle East and North Africa, based in Amman, Jordan.

Dr Anna Reuss is Head of the Friedrich-Ebert-Stiftung’s office for South Sudan.

Source: International Politics and Society (IPS) published by the Global and European Policy Unit of the Friedrich-Ebert-Stiftung, Hiroshimastrasse 28, D-10785 Berlin

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);